Both are used in interventional mental-health care, but they are not interchangeable products. Their regulatory status, administration, insurance pathways, and cost structures differ substantially.
| IV ketamine | Spravato | |
|---|---|---|
| Drug | Ketamine | Esketamine |
| Psychiatric FDA status | Off-label | FDA-approved for specified depressive indications |
| Administration | IV infusion in clinic | Nasal spray under healthcare supervision |
| Insurance | Frequently self-pay for psychiatric use | Major insurers publish coverage/authorization pathways |
| Cost comparison | Often quoted per infusion or induction course | Member cost depends heavily on insurance and authorization |
There is no universal answer. A patient with qualifying insurance coverage may find Spravato dramatically less expensive out of pocket than self-pay IV treatment. Another patient may choose IV ketamine based on clinical recommendations, access, treatment preferences, or other factors.
That is a clinical decision to make with a qualified healthcare professional. Ketamine Match does not determine medical eligibility. Our role is to help users compare the practical dimensions that often influence where they seek an evaluation.
The FDA distinguishes compounded/off-label ketamine from FDA-approved Spravato. FDA safety communication
Answer 13 questions about insurance, budget, location, treatment preference, and care preferences. Ketamine Match will rank the options in our NYC provider dataset.
Show my matches